The future of neuroprotection in stroke

Á Chamorro, EH Lo, A Renú, K van Leyen… - Journal of Neurology …, 2021 - jnnp.bmj.com
Investigators acknowledge the limitations of rodent or non-human primate stroke models,
hundreds of putative neuroprotectants have been evaluated in preclinical models, but not …

The future of neuroprotection in stroke

Á Chamorro, EH Lo, A Renú… - Journal of Neurology …, 2021 - search.proquest.com
Investigators acknowledge the limitations of rodent or non-human primate stroke models,
hundreds of putative neuroprotectants have been evaluated in preclinical models, but not …

The future of neuroprotection in stroke.

Á Chamorro, EH Lo, A Renú, K van Leyen… - Journal of Neurology …, 2020 - europepmc.org
Investigators acknowledge the limitations of rodent or non-human primate stroke models,
hundreds of putative neuroprotectants have been evaluated in preclinical models, but not …

The future of neuroprotection in stroke

Á Chamorro, EH Lo, A Renú… - Journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Investigators acknowledge the limitations of rodent or non-human primate stroke models,
hundreds of putative neuroprotectants have been evaluated in preclinical models, but not …

[PDF][PDF] The future of neuroprotection in stroke

Á Chamorro, EH Lo, A Renú, K van Leyden, PD Lyden - researchgate.net
Investigators acknowledge the limitations of rodent or non-human primate stroke models,
hundreds of putative neuroprotectants have been evaluated in preclinical models, but not …

The future of neuroprotection in stroke

Á Chamorro, EH Lo, A Renú, K van Leyden… - Journal of Neurology …, 2020 - jnnp.bmj.com
Investigators acknowledge the limitations of rodent or non-human primate stroke models,
hundreds of putative neuroprotectants have been evaluated in preclinical models, but not …

[PDF][PDF] The future of neuroprotection in stroke

Á Chamorro, EH Lo, A Renú, K van Leyden, PD Lyden - researchgate.net
Investigators acknowledge the limitations of rodent or non-human primate stroke models,
hundreds of putative neuroprotectants have been evaluated in preclinical models, but not …